Roger Harrison to Cell Line, Tumor
This is a "connection" page, showing publications Roger Harrison has written about Cell Line, Tumor.
Connection Strength
1.284
-
Immunogenic Treatment of Metastatic Breast Cancer Using Targeted Carbon Nanotube Mediated Photothermal Therapy in Combination with Anti-Programmed Cell Death Protein-1. J Pharmacol Exp Ther. 2024 Jun 21; 390(1):65-77.
Score: 0.176
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.114
-
Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer. Nanotechnology. 2018 Jan 19; 29(3):035101.
Score: 0.113
-
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Mol Cancer Ther. 2017 09; 16(9):1855-1865.
Score: 0.108
-
Annexin-directed ß-glucuronidase for the targeted treatment of solid tumors. Protein Eng Des Sel. 2017 Feb; 30(2):85-94.
Score: 0.105
-
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. Pancreas. 2015 Aug; 44(6):945-52.
Score: 0.095
-
Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. J Biomed Sci. 2014 Jul 22; 21:65.
Score: 0.089
-
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS One. 2013; 8(10):e76403.
Score: 0.084
-
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Invest. 2013 Oct; 31(8):505-10.
Score: 0.084
-
Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 2013 Sep 20; 24(37):375104.
Score: 0.083
-
Vascular targeted single-walled carbon nanotubes for near-infrared light therapy of cancer. Nanotechnology. 2011 Nov 11; 22(45):455101.
Score: 0.073
-
Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Lett. 2011 Feb 28; 301(2):177-84.
Score: 0.069
-
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res. 2006 May-Jun; 26(3A):1745-51.
Score: 0.050
-
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 2009; 84(5):271-5.
Score: 0.016
-
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Anticancer Res. 2007 Sep-Oct; 27(5A):3435-9.
Score: 0.014
-
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemother Pharmacol. 2003 Oct; 52(4):270-6.
Score: 0.010